NCT02219997

Brief Summary

The purpose of this study is to compare the reaction time (as measured by braking reaction time in seconds during simulated driving) under glare and no-glare conditions in subjects implanted with ACRYSOF® IQ intraocular lenses (IOLs) to subjects implanted with clear IOLs. This study will enroll subjects previously implanted with IOLs in both eyes for at least 3 months.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2014

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 18, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 19, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2015

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

May 26, 2016

Completed
Last Updated

May 26, 2016

Status Verified

April 1, 2016

Enrollment Period

5 months

First QC Date

August 18, 2014

Results QC Date

February 24, 2016

Last Update Submit

April 20, 2016

Conditions

Keywords

CataractIntraocular lens (IOL)AcrySof

Outcome Measures

Primary Outcomes (1)

  • Change in Braking Reaction Time From No-glare to Glare

    Braking reaction time (time to brake, in seconds) was assessed using a driving simulator in no-glare and glare conditions. The subject was presented with a driving scenario during which an obstruction (car pulling over from either side of the road in a random fashion) was presented. Subjects braked in an attempt to avoid colliding with the obstruction, and the braking reaction time was recorded. The experiment was repeated with a glare source present. Both assessments (no-glare and glare) occurred on the same day. Change in braking reaction time was calculated as glare minus no-glare.

    Visit 2, up to Day 30

Secondary Outcomes (2)

  • Change in Braking Reaction Time From No-glare to Glare (Clear IOLs)

    Visit 2, Up to Day 30

  • Change in Braking Reaction Time From No-glare to Glare (ACRYSOF® IQ IOL + Placebo Filter; Clear IOL + BLF)

    Visit 2, Up to Day 30

Study Arms (2)

ACRYSOF IQ IOL

EXPERIMENTAL

ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours

Device: Clear clip-on glassesDevice: ACRYSOF® IQ IOL

Clear IOL

ACTIVE COMPARATOR

Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total

Device: Clear clip-on glassesDevice: Blue light filter clip-on glassesDevice: Clear IOL

Interventions

Clip-on glasses with no blue light filtering properties used as a placebo

ACRYSOF IQ IOLClear IOL

Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs

Clear IOL

AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted

ACRYSOF IQ IOL
Clear IOLDEVICE

Clear IOL, previously implanted

Clear IOL

Eligibility Criteria

Age65 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Pseudophakes with ACRYSOF® IQ monofocal IOLs or clear (no blue light filter) IOLs in both eyes for at least 3 months.
  • Willing and able to understand and sign an informed consent form.
  • Corrected visual acuity (CVA) of 20/40 or better.
  • Have a valid driver's license.
  • Depth perception of at least 100 arc seconds.

You may not qualify if:

  • Ocular pathology, degeneration, or media opacity.
  • Color vision defect.
  • Use of ocular or systemic medications that impact macular pigment density or reaction time, including but not limited to, lutein, zeaxanthin, barbiturates, tranquilizers or amphetamines.
  • System conditions affecting connective tissue or sensory-motor coordination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Results Point of Contact

Title
Global Brand Med Affairs Lead, VGR
Organization
Alcon Research, Ltd.

Study Officials

  • Sr Clinical Manager, GCRA-Global Med Affairs, Operations

    Alcon Research

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 18, 2014

First Posted

August 19, 2014

Study Start

October 1, 2014

Primary Completion

March 1, 2015

Study Completion

March 1, 2015

Last Updated

May 26, 2016

Results First Posted

May 26, 2016

Record last verified: 2016-04